GH1 and craniopharyngioma: Regarding the management of growth hormone therapy in BTS, only 45% of participants would start GH treatment in a patient with a non-craniopharyngioma brain tumor after 1 year disease-free, as suggested by the current guidelines (18), while the remaining 55% would wait 24 months or more indicating uncertainty in treating with GHT a previous tumoral patient or unawareness of recommendations.